Intrexon and Fibrocell hit an FDA speed bump; Sarepta schedules DMD update;

@FierceBiotech: ICYMI: Aduro adds checkpoint inhibitors to a 'breakthrough' mix in $32M buyout. Article | Follow @FierceBiotech

@JohnCFierce: Think the drug pricing issue is going away? Washington Post: The secret truth. Report | Follow @JohnCFierce

@DamianFierce: As a longtime appreciator of dumb corporate M&A codenames, "Project Potsticker" is a solid addition. Bloomberg story | Follow @DamianFierce

> Intrexon ($XON) and Fibrocell Science ($FCSC) are postponing plans for a clinical trial of their gene therapy after the FDA requested more preclinical toxicology data. The companies expect to get back on track in the second quarter of next year. News

> Sarepta Therapeutics ($SRPT) is planning to provide an update Oct. 1 on its efforts to develop a treatment for Duchenne muscular dystrophy. More

Medical Device News

@FierceMedDev: ICYMI: Study: 3-D tissue marker helps improve breast cancer monitoring, aids recovery. Article | Follow @FierceMedDev

@VarunSaxena2: Four key medical device recalls of 2015. Feature | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: EU regulators crack down on Brazilian devicemaker for implant safety scare. Article | Follow @EmilyWFierce

> Pathway Genomics' direct-to-consumer cancer diagnostic earns FDA warning letter. Report

> Sientra off by more than 50% after it discloses CE mark suspension for its contract manufacturer. More

> FDA panel grills Bayer over Essure safety. Story

Pharma News

@FiercePharma: Investors trounce Aratana on dashed hopes for canine lymphoma drugs. FierceAnimalHealth article | Follow @FiercePharma

@EricPFierce: Sun Pharma unit Mutual Pharma recalls 216,766 bottles that may have chemical leaching labels. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Proud to say my home state is like, basically, the champion of pumpkin-growing. Where America's pumpkins come from. More | Follow @CarlyHFierce

> Novartis scores EU rec for blockbuster-to-be Entresto. News

> Alexion sues Canada over Soliris price cut attempt as drug cost debate explodes on center stage. Story

> Shire chalks up victory in Vyvanse patent battle. Report